Literature DB >> 11105952

Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei).

D L Fritz1, P Vogel, D R Brown, D Deshazer, D M Waag.   

Abstract

Sixty male BALB/c mice were inoculated intraperitoneally with either a sublethal or a lethal dose of Burkholderia mallei China 7 strain, then killed at multiple time points postinoculation. Histopathologic changes were qualitatively similar in both groups and consisted of pyogranulomatous inflammation. In sublethal study mice, changes were first seen at 6 hours in mediastinal lymph nodes, then in spleen, liver, peripheral lymph nodes, and bone marrow at day 3. These changes generally reached maximal incidence and severity by day 4 but decreased by comparison in all tissues except the liver. Changes were first seen in lethal study mice also at 6 hours in mediastinal lymph nodes and in spleens. At day 1, changes were present in liver, peripheral lymph nodes, and bone marrow. The incidence and severity of these changes were maximal at day 2. In contrast to sublethal study mice, the incidence and severity of the changes did not decrease through the remainder of the study. The most significant difference between the two groups was the rapid involvement of the spleen in the lethal study mice. Changes indicative of impaired vascular perfusion were more frequently seen in the sublethal study mice. Our findings indicate that mice are susceptible to B. mallei infection and may serve as an appropriate model for glanders infection in a resistant host such as human beings. Additionally, by immunoelectron microscopy, we showed the presence of type I O-antigenic polysaccharide (capsular) antigen surrounding B. mallei.

Entities:  

Mesh:

Year:  2000        PMID: 11105952     DOI: 10.1354/vp.37-6-626

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  24 in total

1.  Bacteriophage-associated genes responsible for the widely divergent phenotypes of variants of Burkholderia pseudomallei strain MSHR5848.

Authors:  David DeShazer; Sean Lovett; Joshua Richardson; Galina Koroleva; Kathleen Kuehl; Kei Amemiya; Mei Sun; Patricia Worsham; Susan Welkos
Journal:  J Med Microbiol       Date:  2019-01-10       Impact factor: 2.472

2.  Inactivation of Burkholderia mallei in Equine Serum for Laboratory Use.

Authors:  Lorraine Perrett; Ian Mawhinney
Journal:  J Clin Microbiol       Date:  2015-02-11       Impact factor: 5.948

3.  Evaluation of PCR, DNA hybridization and immunomagnetic separation - PCR for detection of Burkholderia mallei in artificially inoculated environmental samples.

Authors:  S Merwyn; S Kumar; G S Agarwal; G P Rai
Journal:  Indian J Microbiol       Date:  2010-03-05       Impact factor: 2.461

4.  Use of Immunohistochemistry to Demonstrate In Vivo Expression of the Burkholderia mallei Virulence Factor BpaB During Experimental Glanders.

Authors:  Shawn M Zimmerman; Mackenzie E Long; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Vet Pathol       Date:  2017-11-16       Impact factor: 2.221

5.  Pathological findings and diagnostic implications of a rhesus macaque (Macacca mulatta) model of aerosol exposure to Burkholderia mallei (glanders).

Authors:  Samuel L Yingst; Paul Facemire; Lara Chuvala; David Norwood; Mark Wolcott; Louis Huzella
Journal:  J Med Microbiol       Date:  2015-04-07       Impact factor: 2.472

6.  Quorum sensing: a transcriptional regulatory system involved in the pathogenicity of Burkholderia mallei.

Authors:  Ricky L Ulrich; David Deshazer; Harry B Hines; Jeffrey A Jeddeloh
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Authors:  Kei Amemiya; Gary V Bush; David DeShazer; David M Waag
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

8.  Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Authors:  Andrew Goodyear; Lisa Kellihan; Helle Bielefeldt-Ohmann; Ryan Troyer; Katie Propst; Steven Dow
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

Review 9.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

10.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.